• Oniria Therapeutics

  Led · Seed · May 2023

  Oniria Therapeutics is a Barcelona-based biopharmaceutical company developing drugs to eliminate persistent tumour cells that remain after conventional cancer treatment. Its lead candidate, ONR-001, is described as a first-in-class drug aimed at removing those persistent cells. The company is in the preclinical phase and intends to use recently raised funds to continue advancing development of ONR-001. Oniria focuses on precision oncology and targeting the cells responsible for disease progression into fatal phases. The company was established in 2021 as a spin-off of the Vall d’Hebron Institute of Oncology (VHIO), University of Barcelona and ICREA. The founding team includes Dr Héctor G. Palmer, Esther Riambau (CEO), Dr Isabel Puig, Dr Josep Tabernero, Dr Xavier Barril and Dr Carles Galdeano.

• Vaxdyn

  Participated · Equity · Mar 2021

  Vaxdyn develops multi‑pathogen vaccine candidates aimed at preventing infections caused by antibiotic‑resistant bacteria. Headquartered in Seville, Spain, the company works with an international network of collaborators to target high‑risk populations (chronic lung, liver, kidney disease, immunocompromised patients, nursing‑home and hospital settings). Its vision is to create specific immunity in these groups and to reduce antibiotic use worldwide following a One‑Health approach. Recent financing activity includes share acquisitions by Bionova Capital and Arquimea Group (each valued at €300,000 in two tranches) and a €100,000 capital increase from the Mind the Gap Program. Vaxdyn also benefits from CARB‑X support: up to $7.3 million in non‑dilutive, milestone‑based funding to advance its lead vaccine candidate through a first‑in‑human study. Strategic investors are positioned to contribute sector expertise and cross‑sector technological support to the company’s vaccine development efforts.

No current team members are available.